Roseburia
Selected indexed studies
- Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. (Gut, 2023) [PMID:37491158]
- Roseburia intestinalis-derived butyrate alleviates neuropathic pain. (Cell Host Microbe, 2025) [PMID:39706182]
- Roseburia intestinalis sensitizes colorectal cancer to radiotherapy through the butyrate/OR51E1/RALB axis. (Cell Rep, 2024) [PMID:38412097]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Roseburia hominis improves host metabolism in diet-induced obesity. (2025) pubmed
- Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8(+) T cells. (2023) pubmed
- Roseburia intestinalis-derived butyrate alleviates neuropathic pain. (2025) pubmed
- Roseburia intestinalis sensitizes colorectal cancer to radiotherapy through the butyrate/OR51E1/RALB axis. (2024) pubmed
- Roseburia inulinivorans increases muscle strength. (2026) pubmed
- Commensal cow Roseburia reduces gut-dysbiosis-induced mastitis through inhibiting bacterial translocation by producing butyrate in mice. (2022) pubmed
- Roseburia intestinalis stimulates TLR5-dependent intestinal immunity against Crohn's disease. (2022) pubmed
- Roseburia intestinalis: A possible target for vascular calcification. (2024) pubmed
- Roseburia intestinalis-derived extracellular vesicles ameliorate colitis by modulating intestinal barrier, microbiome, and inflammatory responses. (2024) pubmed
- Roseburia spp.: a marker of health? (2017) pubmed